Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 340 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Essential amino acids Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

NCT03679780
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions
BQ-788, BQ-123, L-Arginine, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Lactated Ringer's
Drug
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 35 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 2 Interventional

Tryptophan and Behavior Therapy for Cocaine Abuse - 1

NCT00000324
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Tryptophan
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.

NCT00416468
View directory record Official record
Conditions
Healthy
Interventions
Aliskiren, Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 21, 2007 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

NCT00549770
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Not applicable Interventional

EAA Intake to Optimize Protein Anabolism in COPD

NCT01173354
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Free balanced amino acid mixture, Free essential amino acid mixture
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 2, 2026, 3:59 AM EDT
Withdrawn Phase 4 Interventional

Blood Pressure Lowering in Acute Stroke Trial

NCT01400256
View directory record Official record
Conditions
Stroke, Acute
Interventions
Valsartan
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril

NCT00657241
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR, Valsartan
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 2, 2026, 3:59 AM EDT
Completed No phase listed Observational

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

NCT05096039
View directory record Official record
Conditions
Heart Failure
Interventions
Sacubitril/valsartan, ACEI or ARB and no sacubitril/valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,614,719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

Comparison of Botulinum Toxin Injections in Forearm FLexor Plus EXtensor Muscles vs. Flexor Muscles Alone for Treatment of Essential Hand Tremor(FLEX-D ET)

NCT02909907
View directory record Official record
Conditions
Essential Tremor
Interventions
Botulinum toxin, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers

NCT00048477
View directory record Official record
Conditions
Nitric Oxide, Endothelium-Derived Relaxing Factor, Healthy
Interventions
L-NMMA and Sodium Nitrite
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplement and Acute Resistance Exercise

NCT06801951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
acute resistance exercise with oral nutrition supplementation, stable tracer infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 2, 2026, 3:59 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 2, 2026, 3:59 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

NCT03686657
View directory record Official record
Conditions
Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions
Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High
Drug
Lead sponsor
ARKAY Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

NCT00409578
View directory record Official record
Conditions
Post Acute Coronary Syndrome, Myocardial Ischemia
Interventions
Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Investigative Site, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 2, 2026, 3:59 AM EDT
Active, not recruiting Not applicable Interventional

Assessing The Effects of Exercise, Protein, and Electric Stimulation On Intensive Care Unit Patients Outcomes

NCT02509520
View directory record Official record
Conditions
Muscle Weakness, Critical Illness, Sarcopenia
Interventions
MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

NCT02924727
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 2, 2026, 3:59 AM EDT
Terminated Not applicable Interventional Results available

Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients

NCT02606279
View directory record Official record
Conditions
HIV, Aging, Sarcopenia, Angiotensin Receptor Antagonists
Interventions
valsartan, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Results available

Black Education and Treatment of Hypertension (BEAT HTN)

NCT00661895
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Lisinopril, Lisinopril and Hydrochlorothiazide, Nifedipine XL, Metoprolol tartrate, Atenolol, Valsartan, Doxazosin, Clonidine, Hydralazine, Metoprolol succinate, Amlodipine
Drug
Lead sponsor
Creighton University
Other
Eligibility
25 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Sep 2, 2026, 3:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Stable Isotopes- Adults With Obesity

NCT07020741
View directory record Official record
Conditions
Obese Patients (BMI ≥ 30 kg/m²), Glucose Metabolism, Protein Metabolism
Interventions
Indispensable Amino Acid Oxidation, Stable Isotope Oral Glucose Tolerance Test
Procedure
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
19 Years to 59 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS

NCT03717935
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions
Essential Amino Acid (EAA) Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 2, 2026, 3:59 AM EDT
Not listed No phase listed Observational

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

NCT04743063
View directory record Official record
Conditions
Heart Failure, Systolic, Frailty
Interventions
sacubitril/valsartan, Angiotensin II Receptor Blockers
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
40,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Sep 2, 2026, 3:59 AM EDT
Recruiting Phase 2 Interventional

Essential Amino Acid Supplementation for Femoral Fragility Fractures

NCT06050668
View directory record Official record
Conditions
Femoral Fracture, Fragility Fracture, Muscle Atrophy
Interventions
Essential Amino Acid Supplementation
Combination Product
Lead sponsor
Michael C Willey
Other
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Iowa City, Iowa • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 2, 2026, 3:59 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms

NCT04629651
View directory record Official record
Conditions
Bone Marrow Fibrosis, Myeloproliferative Neoplasm
Interventions
Captopril
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 2, 2026, 3:59 AM EDT
Not listed Phase 4 Interventional

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

NCT01095822
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Aliskiren + Valsartan
Drug
Lead sponsor
HeartDrug Research LLC
Other
Eligibility
21 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Sep 2, 2026, 3:59 AM EDT